{"id":"W2749902584","doi":"10.1182/blood.v128.22.1922.1922","title":"Treatment-Free Remission Accomplished By Dasatinib (TRAD): Preliminary Results of the Pan-Canadian Tyrosine Kinase Inhibitor Discontinuation Trial","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; London Health Sciences Centre; University of Alberta; McGill University Health Centre; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital de l'Enfant-Jésus; Université de Montréal; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; University Health Network; CancerCare Manitoba; Ottawa Hospital; Dalhousie University; University of Toronto","funders":"","keywords":"Discontinuation; Dasatinib; Medicine; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Imatinib mesylate; Myeloid leukemia; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002050322,0.00050513,0.0007389558,0.000150037,0.00053606,0.00057501,0.0005497173,0.0004652532,0.002525467],"category_scores_gemma":[0.00168175,0.00009930848,0.0008065853,0.0005347044,0.0004586295,0.0002690556,0.0002387558,0.0009424139,0.0001998895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004094141,"about_ca_system_score_gemma":0.007552214,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1081616,"about_ca_topic_score_gemma":0.3457938,"domain_scores_codex":[0.9992203,0.000282144,0.00004425732,0.0001032436,0.0001968939,0.000153179],"domain_scores_gemma":[0.9987532,0.0002201608,0.0002949121,0.00006803437,0.0001828445,0.000480863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7271653,0.006764948,0.0390234,0.001699536,0.002941874,0.0002259789,0.0003674602,0.001375405,0.006296839,0.0006437619,0.0156096,0.1978858],"study_design_scores_gemma":[0.5102018,0.1011806,0.3437353,0.0003026608,0.004418768,0.0005369251,0.0003641019,0.001594121,0.002516856,0.0005883529,0.03443745,0.0001230344],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758602,0.007842666,0.0002600378,0.001503667,0.00008751792,0.001166822,0.006891858,0.00004539478,0.006341646],"genre_scores_gemma":[0.9888786,0.002638608,0.0004384267,0.0006518667,0.00008226128,0.0003608864,0.004967429,0.00000788697,0.001973999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8918384,"threshold_uncertainty_score":0.215064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0174430824245187,"score_gpt":0.2537875532979919,"score_spread":0.2363444708734732,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}